Search

everythinglearnresearchcommunity

for

Search:↓

Taking 5-α reductase inhibitors for prostate enlargement or hair loss does not significantly raise the risk of erectile dysfunction.

Men with hair loss who take a certain type of medication may experience fewer COVID-19 symptoms.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.

Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

New steroid compounds effectively inhibit 5α-reductase and may treat hair loss.

Blocking CRF1 receptors improved male hormone levels and reduced testicular tumor size in men with a specific adrenal condition.

5 alpha-reductase inhibitors like finasteride may lower prostate cancer risk and improve cancer screening.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.

Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.

JAK inhibitors can help treat alopecia areata but have risks and high costs.

Finasteride slowly binds to 5-alpha-reductase, affecting enzyme stability and inhibitor potency.

5-Alpha-Reductase inhibitors might help slow down hair loss in Frontal Fibrosing Alopecia but are not a primary treatment and need more research.

Higher doses of 5α-reductase inhibitors may lower mortality risk, but low doses increase it.

Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.

Five FDA-approved drugs may help block COVID-19 virus entry.

Drugs targeting the Androgen Receptor are effective for treating prostate cancer and other androgen-related conditions.

Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.

The conclusion is that doctors should be careful when prescribing 5α-reductase inhibitors due to possible serious side effects, and they should discuss these risks with patients.

Compounds 4, 4b, and 4c effectively inhibit an enzyme linked to testosterone conversion without significant toxicity.

A stronger dual 5α-reductase inhibitor could improve treatment for benign prostatic hyperplasia by further reducing DHT levels.

Finasteride does not negatively affect male reproductive function.

Taking medication for hair loss might cause sexual problems.

Higher levels of miR-1199-5p may reduce the effectiveness of certain prostate treatments.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

Taking 5-ARI before prostate laser surgery may lead to more blood changes, longer surgery, and more urinary issues.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.